Advanz Ponders Photofrin Sale As It Weighs Deals in Europe
Advanz Pharma is considering slimming down its US operations as it searches for global product deals and company acquisitions in western Europe to restore sales growth.
You may also be interested in...
The UK’s CMA has reiterated its belief that Advanz Pharma charged excessive and unfair prices for liothyronine in the UK, following a separate ruling that provided detailed guidance on how such matters should be evaluated.
By paying just over US$33 million for two Eisai legacy brands, Advanz Pharma is starting to deliver on its strategy to acquire and license a portfolio of niche off-patent medicines.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.